| Literature DB >> 32863886 |
Qichao Hu1, Shizhang Wei1,2, Jianxia Wen1,2, Wenwen Zhang1, Yinxiao Jiang1, Caiyan Qu3, Junbao Xiang1, Yanling Zhao2, Xi Peng1, Xiao Ma1.
Abstract
BACKGROUND: Non-alcoholic fatty liver (NAFLD) is a chronic disease worldwide, which poses a huge threat to human health. Xiaochaihu decoction is a well-known traditional Chinese medicine prescription. It has been proven effective in treating NAFLD but its mechanism is still unclear.Entities:
Keywords: Immunity regulation; Metabolism regulation; NAFLD; Network pharmacology; Oxidative stress regulation; Xiaochaihu decoction
Year: 2020 PMID: 32863886 PMCID: PMC7450930 DOI: 10.1186/s13040-020-00224-9
Source DB: PubMed Journal: BioData Min ISSN: 1756-0381 Impact factor: 2.522
Fig. 1The network of ingredient-target-disease relation (The blue triangle nodes represent possible active ingredients in Xiaochaihu decoction, the red round nodes represent the targets of drugs and the disease, and the green round nodes represent the common targets of drugs and disease)
Fig. 2The network of ingredients and common targets of drugs and the disease (The blue triangle nodes represent possible active ingredients in Xiaochaihu decoction and the green round nodes represent the common targets of drugs and disease)
Active ingredients of Xiaochaihu decoction in the treatment of NAFLD
| Molecular ID | Ingredient | Degree | Source | OB(%) | DL |
|---|---|---|---|---|---|
| MOL000098 | quercetin | 384 | Chaihu, Dazao, Gancao | 46.45 | 0.39 |
| MOL000422 | kaempferol | 168 | Chaihu, Gancao, Renshen | 41.88 | 0.26 |
| MOL000449 | Stigmasterol | 96 | Banxia, Chaihu, Dazao, Huangqin, Renshen | 43.83 | 1.44 |
| MOL000358 | beta-sitosterol | 90 | Banxia, Dazao, Huangqin, Renshen, Shengjiang | 36.91 | 1.32 |
| MOL000173 | wogonin | 48 | Huangqin | 30.68 | 0.79 |
| MOL000354 | isorhamnetin | 48 | Chaihu,Gancao | 49.6 | 0.31 |
| MOL002714 | baicalein | 48 | Banxia,Huangqin | 33.52 | 0.63 |
| MOL004328 | naringenin | 42 | Gancao | 59.29 | 0.28 |
| MOL000392 | formononetin | 32 | Gancao | 69.27 | 0.21 |
| MOL002773 | beta-carotene | 32 | Dazao | 37.18 | 0.58 |
The main targets of Xiaochaihu decoction in the treatment of NAFLD
| UniProtKB | Target | Degree |
|---|---|---|
| P35354 | PTGS2 | 161 |
| P03372 | ESR1 | 98 |
| P35228 | NOS2 | 93 |
| P37231 | PPARG | 90 |
| P07477 | PRSS1 | 88 |
| P07550 | ADRB2 | 73 |
| P49841 | GSK3B | 67 |
| P19793 | RXRA | 62 |
| Q15788 | NCOA1 | 45 |
| P22303 | ACHE | 38 |
Notes: PTGS2 Prostaglandin-endoperoxide Synthase 2, ESR1 Estrogen Receptor 1, NOS2 Nitric Oxide Synthase 2, PPARG Peroxisome Proliferator Activated Receptor Gamma, PRSS1 serine protease 1, ADRB2 Adrenoceptor Beta 2, GSK3B Glycogen Synthase Kinase 3 Beta, RXRA Retinoid X Receptor Alpha, NCOA1 Nuclear Receptor Coactivator 1, ACHE Acetylcholinesterase
Fig. 3PPI network of potential targets of Xiaochaihu decoction for the treatment of NAFLD
Fig. 4The interaction network of identified targets (AKT1: AKT Serine/Threonine Kinase 1; IL-6: Interleukin 6; JUN: Jun Proto-oncogene; MAPK8: Mitogen-activated Protein Kinase 8; STAT3: Signal Transducer and Activator of Transcription 3; PTGS2: Prostaglandin-endoperoxide Synthase 2; CXCL8: C-X-C Motif Chemokine Ligand 8; CCL2: C-C Motif Chemokine Ligand 2; IL1B: Interleukin 1 Beta; VEGFA: Vascular Endothelial Growth Factor A)
Fig. 5The top 10 of GO enrichment analysis (A Representative bubble plots of biological progress of core targets. B Representative bubble plots of cellular components of core targets. C Representative bubble plots of molecular function of core targets. Gene Ratio = count / set size)
Fig. 6Results of KEGG Analysis. a The top 20 signaling pathways from KEGG analysis; b The disease-pathway-target interaction network of Xiaochaihu decoction for NAFLD (The purple node represents NAFLD, the yellow nodes represent pathways related to oxidative stress, the red nodes represent pathways related to immunity, the blue node represents the pathway related to metabolism and the green nodes represent targets)
Information of potential targets and signaling pathways
| ID | Pathway | Counts | |
|---|---|---|---|
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.12E-25 | 24 |
| hsa05160 | Hepatitis C | 7.08E-18 | 22 |
| hsa05418 | Fluid shear stress and atherosclerosis | 1.16E-17 | 21 |
| hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 2.70E-17 | 23 |
| hsa05222 | Small cell lung cancer | 5.79E-16 | 17 |
| hsa05162 | Measles | 2.88E-15 | 19 |
| hsa04657 | IL-17 signaling pathway | 1.75E-14 | 16 |
| hsa05163 | Human cytomegalovirus infection | 2.20E-14 | 22 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 1.72E-13 | 18 |
| hsa05145 | Toxoplasmosis | 3.04E-13 | 16 |
| hsa05161 | Hepatitis B | 7.49E-13 | 18 |
| hsa05142 | Chagas disease (American trypanosomiasis) | 1.15E-12 | 15 |
| hsa05210 | Colorectal cancer | 1.63E-12 | 14 |
| hsa05164 | Influenza A | 1.73E-12 | 18 |
| hsa05169 | Epstein-Barr virus infection | 3.02E-12 | 19 |
| hsa04066 | HIF-1 signaling pathway | 3.13E-12 | 15 |
| hsa05212 | Pancreatic cancer | 5.57E-12 | 13 |
| hsa04659 | Th17 cell differentiation | 3.54E-11 | 14 |
| hsa05215 | Prostate cancer | 1.38E-10 | 13 |
| hsa04931 | Insulin resistance | 5.44E-10 | 13 |
Fig. 7Distribution of the target proteins of Xiaochaihu decoction on the predicted pathways (The red nodes are potential target proteins of Xiaochaihu decoction, while the orange nodes are relevant targets in the pathway)